Arvinas, Inc. - Common Stock (ARVN)

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028.

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.